APLM Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Apollomics Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerAPLM

Market Cap31.9M

Cash RunwayRunway < 6 months

Next Catalyst2027-01-31

Public Research Snapshot

Apollomics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Uproleselan in Relapsed/Refractory AML (Phase 3) using Small Molecule.

Pipeline

Asset	Indication	Modality	Stage	Public Note
APL-101	Bioequivalence	Small Molecule	Phase 1	Public pipeline row
Uproleselan	Relapsed/Refractory AML	n/a	Phase 3	Public pipeline row
APL-501	Hepatocellular Carcinoma \| Renal Cell Carcinoma	Monoclonal Antibody	Phase 1 \| Phase 2	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Clinical Trial Completion	2027-01-31	APL-101	Low

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT03655613	Phase 1 \| Phase 2	TERMINATED	20	2021-12-15
NCT05367388	Phase 1	UNKNOWN	48	2022-11
NCT04839341	Phase 1	COMPLETED	12	2024-06-28
NCT05054543	Phase 3	TERMINATED	140	2024-08-22
NCT04743505	Phase 1 \| Phase 2	ACTIVE_NOT_RECRUITING	27	2027-01-31

Scientific Context

asset_name | APL-101
catalyst_date_estimated | 2027-01-31
catalyst_type | Clinical Trial Completion
clinical_stage | Phase 1
clinical_stage | Phase 1 | Phase 2

Want the full APLM research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.